Nebenwirkungen · NexoBrid
NexoBrid 5 g powder and gel for gel · Abschnitt 4.8 · PDF-Seite 10
HOS-213909 · Präparat HOS-155226
Tachycardia In pooled adult population from phase 2 and 3 studies (MW2001, MW2002, MW2004, MW2005, MW2008 and MW2010), 2.9% of patients experienced tachycardia in temporal proximity to this medicinal product treatment. No tachycardia was reported in the SOC and gel vehicle arms. In pooled paediatric population from studies MW2004, MW2008, and MW2012, tachycardia was reported with lower incidence in the medicinal product treated patients (1.1 %) compared SOC treated patients (3.5%). Alternative causes of tachycardia (e.g., the general burn condition, procedures causing pain, fever and dehydration) should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-03T16:44:00Z · SHA-256 0e966e92cc19adf0ef382cd0ae4ca84db51705148a696b737819286b20db4bab · Passage 7ec97977f0b8f77b54e4debbde554787ec9df2739cb07f0d3a14e200129cd4e2 · Zeichen 5186–5811 im Abschnitt